TELA Bio, Inc. (TELA)
| Market Cap | 31.43M -54.9% |
| Revenue (ttm) | 79.91M +6.1% |
| Net Income | -41.18M |
| EPS | -0.78 |
| Shares Out | 44.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,082 |
| Open | 0.6680 |
| Previous Close | 0.6500 |
| Day's Range | 0.6501 - 0.7000 |
| 52-Week Range | 0.5011 - 1.8700 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 2.10 (+200.0%) |
| Earnings Date | Aug 10, 2026 |
About TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile... [Read more]
Financial Performance
In 2025, TELA Bio's revenue was $80.28 million, an increase of 15.84% compared to the previous year's $69.30 million. Losses were -$38.83 million, 2.62% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TELA stock is "Buy." The 12-month stock price target is $2.1, which is an increase of 200.00% from the latest price.
News
Tela Bio reports Q2 EPS (20c), consensus (18c)
Reports Q2 revenue $19.29M, consensus $20.01M. “Unfortunately, the financial performance of the business does not reflect the superiority of the portfolio. Our second quarter revenue was negatively im...
Tela Bio withdraws FY26 guidance
The company said, “The Company has withdrawn full-year guidance and will provide an update in the future.”
TELA Bio Earnings Call Transcript: Q2 2026
Q2 2026 revenue declined 4% year-over-year, mainly due to lower PRS sales and competitive pressures, while international and hernia segments showed growth. Leadership transition and cost reduction initiatives are underway, with guidance withdrawn pending a new plan.
TELA Bio Earnings release: Q2 2026
TELA Bio released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
TELA Bio Quarterly report: Q2 2026
TELA Bio has published its Q2 2026 quarterly earnings report on August 10, 2026.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
Tela Bio appoints Heather Getz as CEO
Tela Bio (TELA) announced that the board of directors has appointed Heather Getz as CEO and director, effective immediately. Getz joins Tela Bio having most recently served as executive VP…
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction s...
TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio to Announce Second Quarter 2026 Financial Results
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw 3% revenue growth to $19.1M, driven by a 41% surge in international sales and 16% OviTex unit growth. The company launched OviTex LTR, expanded its field team, and reaffirmed 8%+ full-year revenue growth guidance, with strong momentum expected in the second half.
TELA Bio Earnings release: Q1 2026
TELA Bio released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
TELA Bio Quarterly report: Q1 2026
TELA Bio has published its Q1 2026 quarterly earnings report on May 12, 2026.
TELA Bio Reports First Quarter 2026 Financial Results
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today re...
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...
TELA Bio Proxy statement: Proxy filing
TELA Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
TELA Bio Proxy statement: Proxy filing
TELA Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
TELA Bio to Announce First Quarter 2026 Financial Results
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction so...
Tela Bio price target lowered to $3 from $5 at Citizens
Citizens analyst David Turkaly lowered the firm’s price target on Tela Bio (TELA) to $3 from $5 and keeps an Outperform rating on the shares. Tela Bio’s two main biologic…
Tela Bio price target lowered to $2 from $3 at Lake Street
Lake Street lowered the firm’s price target on Tela Bio (TELA) to $2 from $3 and keeps a Buy rating on the shares following an “approximately in line” Q4 and…
Tela Bio price target lowered to $2 from $4 at Canaccord
Canaccord lowered the firm’s price target on Tela Bio (TELA) to $2 from $4 and keeps a Buy rating on the shares. The firm said they posted decent Q4 results…
Tela Bio price target lowered to $1 from $1.25 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio (TELA) to $1 from $1.25 and keeps a Neutral rating on the shares. The firm notes the…
TELA Bio Earnings Call Transcript: Q4 2025
Delivered 16% revenue growth in 2025 and record Q4 results amid major commercial restructuring, with strong European performance and new product launches. 2026 guidance is for at least 8% revenue growth, reflecting prudence as a large cohort of new sales reps ramps up.
TELA Bio Annual report: Q4 2025
TELA Bio has published its Q4 2025 annual report on March 24, 2026.
TELA Bio Earnings release: Q4 2025
TELA Bio released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.